StockData
ENOVNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31

Enovis CORP

Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 6, 2026
$19.87+0.28 (+1.43%)

Close on Oct 19, 2026

Market cap
$1.14B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jul 3, 2026
Aug 6, 2026Before market open$583.00M$-0.02$0.90
Q1 FY2026
Ended Apr 3, 2026
May 7, 2026Before market open$589.00M$-0.15$0.89
Q4 FY2025
Ended Dec 31, 2025
Feb 26, 2026Before market open$576.00M$-9.07$0.95
Q3 FY2025
Ended Oct 3, 2025
Nov 6, 2025Before market open$549.00M$-9.99$0.75
Q2 FY2025
Ended Jul 4, 2025
Aug 7, 2025Before market open$565.00M$-0.64$0.79
Q1 FY2025
Ended Apr 4, 2025
May 8, 2025Before market open$559.00M$-0.98$0.81
Q4 FY2024
Ended Dec 31, 2024
Feb 26, 2025Before market open$561.00M$-12.06$0.98
Q3 FY2024
Ended Sep 27, 2024
Nov 6, 2024Before market open$505.00M$-0.61$0.73
Q2 FY2024
Ended Jun 28, 2024
Aug 7, 2024Before market open–––
Q1 FY2024
Ended Mar 29, 2024
May 2, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 22, 2024Before market open–––

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted EBITDAnon-GAAP2026$425.00M to $435.00MMaintained
adjusted earnings per sharenon-GAAPFull-year$3.52 to $3.73Maintained
free cash flow conversionFull year25%New
Revenue2026$2.31B to $2.37BMaintained
organic revenue growth20264% to 6% growthMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Enovis filed with the SEC